Development of spanish-portuguese thrombotic thrombocytopenic purpura registry (REPTT): a study proposal of the Spanish Society of Hematology and Hemotherapy (SEHH) whit the Portuguese Society of Hematology (SPH).

[Translated article] New challenges in advanced therapies.

Megías-Vericat JE; (...); Poveda Andrés JL

Article. 10.1016/j.farma.2024.05.001. 2024

Belantamab Mafodotin in Combination with VRd for the Treatment of Newly Diagnosed Transplant Eligible Multiple Myeloma Patients: Results from the Phase II, Open Label, Multicenter, GEM-BELA-VRd Trial

Gonzalez-Calle, Veronica; (...); Mateos, Maria-Victoria

Meeting Abstract. https://doi.org/10.1182/blood-2022-162584. 2024

Curative Strategy for High-Risk Smoldering Myeloma: Carfilzomib, Lenalidomide, and Dexamethasone (KRd) Followed by Transplant, KRd Consolidation, and Rd Maintenance.

Mateos, Maria-Victoria; (...); San-Miguel, Jesus F

Article. 10.1200/JCO.23.02771. 2024

• 
• 
• 5

  

Epidemiology of Hereditary Thrombotic Thrombocytopenic Purpura (TTP) in Spain: Preliminary Results of a Study of the Spanish TTP Registry (REPTT)

Segui, Ines Gomez; (...); Garma, Julio Del Rio

Meeting Abstract. 2024

Gastric Bleeding in Stem Cell Transplantation: A Focus on Gastric Vascular Ectasia Under Post-Transplant Cyclophosphamide, Sirolimus, and Mycophenolate Mofetil Prophylaxis.

Eirís J; (...); Sanz J

Article. 10.1016/j.jtct.2024.10.009. 2024

Germline assessment for alloHSCT candidates over 50 years: A 'Fast-Track' screening in myeloid neoplasms.

Torres-Esquius S; (...); Jerez A

Article. 10.1111/bjh.19460. 2024

High-risk cytogenetic abnormalities in multiple myeloma: PETHEMA-GEM experience

Gonzalez-Calle, Veronica; (...); Gutierrez, Norma C.

Article. 10.1002/hem3.70031. 2024

IDIOPATHIC UPPER GASTROINTESTINAL BLEEDING AFTER ALLOGENEIC STEM CELL TRANSPLANTATION: AN UNPRECEDENTED COMPLICATION

Eiris, Juan; (...); Balaguer-Rosello, Aitana

Meeting Abstract. 2024

Immune reconstitution after single-unit umbilical cord blood transplantation using anti-thymoglobulin and myeloablative conditioning in adults with hematological malignancies.

Cordón L; (...); Sanz J

Article. 10.1007/s00277-024-05758-0. 2024

• 
• 1

  

Incidence, risk factors and therapy response of acute graft-versus-host disease after myeloablative hematopoietic stem cell transplantation with posttransplant cyclophosphamide.

Asensi Cantó P; (...); Sanz J

Article. 10.1038/s41409-024-02391-3. 2024

Incidence, risk factors, and outcomes of BK hemorrhagic cystitis in hematopoietic stem cell transplantation from HLA-matched and haploidentical donors with post-transplant cyclophosphamide.

Chorao, Pedro; (...); Sanz, Jaime

Article. 10.1016/j.jtct.2024.12.006. 2024

• 
• 
• 3

  

Longitudinal outcome over four decades of allogeneic stem cell transplantation: a single center experience.

Sanz, Miguel Angel; (...); Sanz, Jaime

Article. 10.1038/s41409-024-02319-x. 2024

• 
• 
• 1

  

New challenges of advanced therapies.

Megías-Vericat JE; (...); Poveda Andrés JL

Article. 10.1016/j.farma.2023.11.008. 2024

RUXOLITINIB IN ACUTE AND CHRONIC GRAFT-VERSUS RECEPTOR DISEASE: LONG-TERM REAL-LIFE EXPERIENCE IN A MULTI-CENTRE STUDY IN PEDIATRIC POPULATION

Escamilla Gomez, Virginia; (...); Garcia Gutierrez, Valentin

Meeting Abstract. 2024

RUXOLITINIB IN ACUTE AND CHRONIC GRAFT-VERSUS-RECEPTOR DISEASE: LONG-TERM REAL-LIFE EXPERIENCE IN A MULTI-CENTRE STUDY

Escamilla Gomez, Virginia; (...); Perez-Simon, Jose Antonio

Meeting Abstract. 2024

Selective IgA Deficiency and Blood Component Transfusion: In Search of the Lost Evidence

Solves, Pilar; (...); de la Rubia, Javier

Article. 10.3390/hemato5020009. 2024

Single-point and kinetics of peripheral residual disease by mass spectrometry to predict outcome in patients with high risk smoldering multiple myeloma included in the GEM-CESAR trial.

Puig N; (...); Mateos MV

Article. 10.3324/haematol.2024.285742. 2024

• 
• 
• 1

  

The genomic profiling of high-risk smoldering myeloma patients treated with an intensive strategy unveils potential markers of resistance and progression.

Medina-Herrera A; (...); Garcia-Sanz R

Article. 10.1038/s41408-024-01053-3. 2024

• 
• 
• 2